Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 11, 23 | -0.11 Decreased by -37.50% | -0.16 Increased by +195.31% |
| Feb 10, 23 | -0.15 Decreased by -200.00% | -0.11 Decreased by -330.58% |
| Nov 10, 22 | -0.11 Increased by +93.08% | -0.10 Decreased by -100.00% |
| Sep 9, 22 | -0.10 Increased by +85.51% | -0.07 Decreased by -612.24% |
| May 11, 22 | -0.08 | -0.05 Decreased by -1.20 K% |
| Feb 11, 22 | -0.05 | -0.06 Increased by +277.78% |
| Sep 22, 21 | -1.59 | -0.03 Decreased by -173.33 K% |
| Jun 21, 21 | -0.69 | -0.04 Decreased by -40.62 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -2.73 M Decreased by -45.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -3.84 M Decreased by -257.33% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -2.61 M Decreased by -68.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -2.32 M Increased by +92.04% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -1.87 M Decreased by -237.03% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -1.07 M Decreased by -227.10% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -1.55 M Decreased by -505.90% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 - | -29.11 M - | Decreased by N/A% - |
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.